Iboxamycin |
Katalog-Nr.GC70838 |
Iboxamycin ist ein potenter Antibiotikandidat mit einem fusionierten bicyclischen Aminosäurerückstand.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2640000-92-4
Sample solution is provided at 25 µL, 10mM.
Iboxamycin is effective against ESKAPE pathogens including strains expressing Erm and Cfr ribosomal RNA methyltransferase enzymes, products of genes that confer resistance to all clinically relevant antibiotics targeting the large ribosomal subunit, namely macrolides, lincosamides, phenicols, oxazolidinones, pleuromutilins and streptogramins[2].
References:
[1]. Mason JD, et al. Practical Gram-Scale Synthesis of Iboxamycin, a Potent Antibiotic Candidate. J Am Chem Soc. 2021;143(29):11019-11025.
[2]. Mitcheltree MJ, et al. A synthetic antibiotic class overcoming bacterial multidrug resistance. Nature. 2021;599(7885):507-512.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *